Sanofi SA
SNY
View Detailed Chart
50.990USD
+0.310+0.61%
Market hours （ET）Quotes delayed by 15 min
124.12BMarket Cap
12.12P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.61%
5 Days
+2.00%
1 Month
+11.70%
6 Months
-5.08%
Year to Date
+5.72%
1 Year
-5.28%
View Detailed Chart
TradingKey Stock Score of Sanofi SA
Currency: USD Updated: 2025-10-29Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sanofi SA's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
9
analysts
Buy
Current Rating
62.574
Target Price
+22.55%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Sanofi SA Highlights
StrengthsRisks
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 171.67%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 171.67%.
Undervalued
The company’s latest PE is 12.26, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 249.99M shares, decreasing 10.55% quarter-over-quarter.
Held by Van Duyn Dodge & E. Morris Cox
Star Investor Van Duyn Dodge & E. Morris Cox holds 71.72M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Sanofi SA Info
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Ticker SymbolSNY
CompanySanofi SA
CEOMr. Paul Hudson, Ph.D.
Websitehttps://www.sanofi.com/
Related Instruments
+4.27%
+1.24%
+1.07%
+0.35%
+0.88%
-1.16%
-2.14%
-0.20%
+0.95%
+0.19%
+0.82%
+2.01%
+2.34%
+4.20%
+1.49%
+0.58%
-0.42%
-8.24%
+12.95%
-0.40%Popular Symbols
